Clinical evaluation of dose escalation of sorafenib in treating advanced renal cell carcinoma after failing to rutine dosage of sorafenib
10.3760/cma.j.issn.1000-6702.2010.01.007
- VernacularTitle:增加索拉非尼剂量治疗常规剂量无效的晚期肾癌的临床评价
- Author:
Hailiang ZHANG
;
Dingwei YE
;
Xudong YAO
;
Shilin ZHANG
;
Bo DAI
;
Yijun SHEN
;
Yao ZHU
;
Yiping ZHU
;
Guohai SHI
;
Chunguang MA
;
Wenjun XIAO
;
Xiaojian QIN
;
Guowen LIN
- Publication Type:Journal Article
- Keywords:
Carcinoma,renal cell;
Neoplasm metastasis;
Sorafenib;
Dose escalation
- From:
Chinese Journal of Urology
2010;31(1):24-27
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and toxicity of sorafenib dose escalation in treating patients with advanced renal cell carcinoma who progressed after rutine dosage of sorafenib.Methods Twenty-four patients with advanced renal cell carcinoma who progressed after 4-22 months' rutine sorafenib treatment(400 mg bid po.) received dose escalation therapy.Nineteen cases were male,5 were female,with the average age of 52 years.Ten cases added their doses to 600 mg bid,and 14 cases escalated to 800 mg bid.Results Four cases(16.7%) progressed after one month's treatment of sorafenib dose escalation,and quited the study.In the other 20 cases,1(4.2%) reached partial remission with a tumor shrinkage of 42.5% and 19(79.2%) maintained stable disease for more than 12 weeks.To Jul 2009,another 10 cases progressed,and the median progression free survival(PFS) for the PR and SD patients was 7 months(3-14 months).The disease control rate was 79.2%,and the median PFS was 5 months(0-14 months) for the entire group of 24 cases.Common toxicities after dose escalation of sorafenib were similar to those of rutine dosage.Although the grade of hand-foot reaction,diarrhea,fatigue,and neutropenia were more severe,no grade 4 toxicities were observed during the treatment.Grade of toxicities would decrease when the time of treatment prolonged.Conclusions Sofafenib dose escalation is a feasible and effective treatment for the patients with advanced renal cell carcinoma who failed to rutine dosage of sorafenib.The disease control rate of this therapy is relatively high.The toxicities do not increase much,and could be well tolerated by most patients.
